Acalabrutinib maintenance after transplant or CAR T for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old.
- You are starting treatment after one of these: autologous stem cell transplant, allogeneic stem cell transplant, or FDA-approved CAR T therapy for large B-cell lymphoma.
- Your lymphoma must be in partial or complete response right before starting the study (timing depends on transplant vs CAR T).
- Your health and lab counts must be strong enough (low infection risk and adequate blood counts, including neutrophils and platelets).
- You must be able to swallow the study pills and take part in frequent study visits/tests.
- You cannot be pregnant or breastfeeding, and if you could become pregnant you must use effective birth control during the study and briefly after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This study tests whether adding acalabrutinib to a reduced-strength chemotherapy plan (R-miniCHOP) works better and is safer for older adults with newly diagnosed diffuse large B-cell lymphoma. It may help you get a more effective treatment while using a dosing approach meant for people who may not tolerate full-strength therapy.
This trial tests whether modified immune cells (CD19 CAR T cells) given with the medicine acalabrutinib can help people with mantle cell lymphoma that has come back or did not respond. It may help by attacking lymphoma cells more strongly and improving disease control after prior treatment.
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.